Hypertriglyceridaemia and the risk of pancreatitis six months post lopinavir/ritonavir initiation
Background: Hypertriglyceridaemia (HTG) is an important risk factor for pancreatitis and cardiovascular disease (CVD), depending on severity. Hypertriglyceridaemia is common in human immunodeficiency virus (HIV) infection and is also a common complication of lopinavir/ritonavir (LPV/r). Objectives:...
Main Authors: | Wilhelm P. Greffrath, Jesslee M. du Plessis, Michelle Viljoen, Marike Cockeran |
---|---|
Format: | Article |
Language: | English |
Published: |
AOSIS
2018-06-01
|
Series: | Southern African Journal of HIV Medicine |
Subjects: | |
Online Access: | https://sajhivmed.org.za/index.php/hivmed/article/view/766 |
Similar Items
-
COVID-19 Hastalarında Lopinavir/Ritonavir ve Favipravir Deneyimi
by: Esma Eroğlu, et al.
Published: (2020-12-01) -
Lopinavir/ritonavir use in Covid-19 infection: is it completely non-beneficial?
by: Adewale Bayode Owa, et al.
Published: (2020-10-01) -
COVID-19 Hastalarında Lopinavir/Ritonavir ve Favipravir Deneyimi
by: Esma Eroğlu, et al.
Published: (2020-12-01) -
The efficacy of nelfinavir and lopinavir/ritonavir in the treatment of HIV-infected pediatric patients
by: V. B. Denisenko,, et al.
Published: (2018-12-01) -
Determination of lopinavir/ritonavir concentrations in four different oral solutions for the application of antiretroviral therapy in very young, HIV-1-infected children
by: Nils von Hentig, et al.
Published: (2021-05-01)